Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed FCF Margin for 10 consecutive years, with 29.39% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 2052.0% year-over-year to 29.39%, compared with a TTM value of 35.42% through Dec 2025, down 1324.0%, and an annual FY2025 reading of 35.42%, down 1324.0% over the prior year.
  • FCF Margin was 29.39% for Q4 2025 at Catalyst Pharmaceuticals, up from 21.86% in the prior quarter.
  • Across five years, FCF Margin topped out at 72.15% in Q3 2022 and bottomed at 9.61% in Q1 2021.
  • Average FCF Margin over 5 years is 42.11%, with a median of 46.26% recorded in 2025.
  • The sharpest move saw FCF Margin surged 3893bps in 2021, then crashed -3456bps in 2025.
  • Year by year, FCF Margin stood at 49.95% in 2021, then surged by 32bps to 65.96% in 2022, then decreased by -24bps to 50.25% in 2023, then dropped by -1bps to 49.91% in 2024, then crashed by -41bps to 29.39% in 2025.
  • Business Quant data shows FCF Margin for CPRX at 29.39% in Q4 2025, 21.86% in Q3 2025, and 48.63% in Q2 2025.